- Home
- SWIN vs AADI Comparison
SWIN vs AADI Comparison
Compare SWIN & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- AADI
- Stock Information
- Founded
- SWIN 2017
- AADI 2011
- Country
- SWIN Hong Kong
- AADI United States
- Employees
- SWIN N/A
- AADI N/A
- Industry
- SWIN
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- AADI Health Care
- Exchange
- SWIN Nasdaq
- AADI Nasdaq
- Market Cap
- SWIN 41.7M
- AADI 49.0M
- IPO Year
- SWIN 2023
- AADI N/A
- Fundamental
- Price
- SWIN $2.49
- AADI $2.30
- Analyst Decision
- SWIN
- AADI Hold
- Analyst Count
- SWIN 0
- AADI 3
- Target Price
- SWIN N/A
- AADI $1.75
- AVG Volume (30 Days)
- SWIN 109.1K
- AADI 117.2K
- Earning Date
- SWIN 12-06-2024
- AADI 11-06-2024
- Dividend Yield
- SWIN N/A
- AADI N/A
- EPS Growth
- SWIN N/A
- AADI N/A
- EPS
- SWIN N/A
- AADI N/A
- Revenue
- SWIN $3,437,000.00
- AADI $25,070,000.00
- Revenue This Year
- SWIN N/A
- AADI $8.10
- Revenue Next Year
- SWIN N/A
- AADI $8.54
- P/E Ratio
- SWIN N/A
- AADI N/A
- Revenue Growth
- SWIN N/A
- AADI 7.80
- 52 Week Low
- SWIN $2.01
- AADI $1.21
- 52 Week High
- SWIN $72.55
- AADI $5.70
- Technical
- Relative Strength Index (RSI)
- SWIN 45.73
- AADI 69.94
- Support Level
- SWIN $2.15
- AADI $2.12
- Resistance Level
- SWIN $2.84
- AADI $2.40
- Average True Range (ATR)
- SWIN 0.23
- AADI 0.12
- MACD
- SWIN 0.01
- AADI 0.02
- Stochastic Oscillator
- SWIN 49.28
- AADI 77.78
About SWIN Solowin Holdings
Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.